Bertucci F, Pages C, Finetti P, et al. CAS  2009;27(1):38–44. Monoclonal antibodies specific for melanocytic tumors distinguish subpopulations of melanocytes. Assessment of copy number status of chromosomes 6 and 11 by FISH provides independent prognostic information in primary melanoma. Pepys MB, Hirschfield GM. Lunavat TR, Cheng L, Einarsdottir BO, Olofsson Bagge R, Veppil Muralidharan S, Sharples RA, Lasser C, et al. 167. 171. Diagnostic biomarkers identify and confirm the presence of cancer to facilitate early detection, prognostic markers forecast the probable course and likely outcomes of a disease regardless of treatment, and predictive biomarkers evaluate the likelihood of benefit from a specific treatment [13]. Serum proteomic fingerprinting discriminates between clinical stages and predicts disease progression in melanoma patients. Privacy J Cell Physiol. Kosaka N, Iguchi H, Ochiya T. Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. In the following sections, we discuss commonly used proteomic, molecular and cellular profiling approaches, the progress and limitations of these emerging technologies, and their contributions to melanoma biomarker discovery (Table 3). 162. Mutations at the mouse microphthalmia locus are associated with defects in a gene encoding a novel basic-helix-loop-helix-zipper protein. 184. Lee JH, Long GV, Boyd S, Lo S, Menzies AM, Tembe V, Guminski A, et al. Hilliard NJ, Krahl D, Sellheyer K. p16 expression differentiates between desmoplastic Spitz nevus and desmoplastic melanoma. 2017; Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, et al. 2010;411(17–18):1319–1324. Circulating vascular endothelial growth factor in cutaneous malignant melanoma. Histopathology. Kulasingam V, Diamandis EP. 2004;91(4):699–702. J Clin Pathol. Diagnosing melanoma patients entering American Joint Committee on Cancer stage IV, C-reactive protein in serum is superior to lactate dehydrogenase. There are many prognostic and predictive biomarkers used clinically in melanoma, and these form the updated version of the 8th edition American Joint Committee on Cancer (AJCC) melanoma staging system [17]. Anjo SI, Santa C, Manadas B. SWATH-MS as a tool for biomarker discovery: from basic research to clinical applications. Mol Oncol. JCAD | The Journal of Clinical and Aesthetic Dermatology. 1994;180(1): 35–42. Liquid biopsies can capture circulating components and offer several advantages to tissue based profiling; they are minimally invasive, can profile clonally divergent, distant metastases without sampling bias, and allow for routine longitudinal tracking of patient response to therapy [16]. A favorable ctDNA profile (i.e. Circulating melanoma cells in the diagnosis and monitoring of melanoma: an appraisal of clinical potential. Perfetto SP, Chattopadhyay PK, Roederer M. Seventeen-colour flow cytometry: unravelling the immune system. Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, Demidov LV, et al. J Exp Med. [185] They help regulate cell proliferation, differentiation, and apoptosis and also affect expression of oncogenes and tumor suppressor genes. Theos AC, Tenza D, Martina JA, et al. Biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy. Chapman PB, Hauschild A, Robert C, et al. Nat Cell Biol. Mactier S, Kaufman KL, Wang P, Crossett B, Pupo GM, Kohnke PL, Thompson JF, et al. [96] While rarely expressed in carcinomas, it is strongly expressed in advanced primary and metastatic melanoma and less so in nevi. Circulating melanoma cells as a potential biomarker to detect metastasis and evaluate prognosis. Gerami P, Wass A, Mafee M, et al. 34. [106–108] It has been proposed that CD10, a zinc-dependent endopeptidase, may affect prognosis by degradation of substances, such as enkephalin and substance P, which are known to suppress tumor progression in melanoma. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, Rutkowski P, et al. [103–105] Melanoma, nevogenesis, and stem cell biology. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. Classifying cancers based on T-cell infiltration and PD-L1. Therefore, patients with tumors that are positive for this BRAF mutation may have improved survival with treatment due to this new treatment. While these biomarkers do facilitate the histopathological diagnosis of melanoma, Melan-A, HMB-45, and tyrosinase all show diminishing sensitivity with advancing stage disease. However, levels of these controls may be deregulated in cancer and spiked in controls may not be practical when dealing with large numbers of biological samples [85]. Clarkson KS, Sturdgess IC, Molyneux AJ. Google Scholar. Shi T, Gao G, Cao Y. Nat Genet. 2017;545:60–5. J Clin Oncol. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, et al. 2015;372:2521–32. [83] 2012;19(2): 620–626. Mitotic rate is currently included in the AJCC as one of the staging criteria because of its correlation with patient survival. S100B protein detection in serum is a significant prognostic factor in metastatic melanoma. Granter SR, Weilbaecher KN, Quigley C, et al. [128,129] Instead, elevated LDH levels have been consistently associated with adverse prognosis and directly correlate with survival in patients with stage IV disease. [6–12] Among the markers considered for use in the histological diagnosis of melanoma are Human Melanoma Black-45 (HMB-45), Melan-A, tyrosinase, microphthalmia transcription factor, and S100 as well as several newer ones (Table 1 and Table 2). 158. Chattopadhyay PK, Perfetto SP, Roederer M. The colorful future of cell analysis by flow cytometry. 142. Melanoma biomarker expression in melanocytic tumor progression: a tissue microarray study. 1998;80(1):171–175. In addition to the previously mentioned biomarkers used to aid in the diagnosis of melanoma, several other biomarkers currently are under investigation, including MUM-1, Mel-5, melanocortin-1, and PNL2 among others. [187] Expression of miRNAs in tissue specimens already show correlation with diagnosis and prognosis. 180. Cancer. As such, current serologic biomarkers detect circulating melanoma cells or secondary evidence of advanced disease, such as LDH. N Engl J Med. [22,58] Like other markers, its sensitivity decreased in metastatic lesions, but only to 92 to 96 percent, which is much better than other currently available biomarkers. Based on the data available so far, this Epigenetics and genetics. However, these studies are limited by the fact that they must be performed on cryopreserved tissue. 147. 37. Immunologic escape and angiogenesis in human malignant melanoma. J Chromatogr A. Horvat S, Mlinaric-Majerski K, Glavas-Obrovac L, et al. Serological and immunohistochemical analysis of S100 and new derivatives as markers for prognosis in patients with malignant melanoma. However, biomarker discovery alone is not sufficient, and more emphasis needs to be directed at validation of newly emerging biomarker candidates to realize their implementation into clinic. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. European journal of cancer (Oxford, England: 1990). C-reactive protein: a critical update. Overexpression of melanoma inhibitory activity (MIA) enhances extravasation and metastasis of A-mel 3 melanoma cells in vivo. Cancer cells that replicate via anaerobic or glycolytic mechanisms have reduced dependence on oxygen for energy production creating a survival advantage. 2015;13:2226–38. 2002;417(6892):949–954. HMB-45 recognizes a 100 kD glycoprotein known as premelanosome protein (Pmel), Pmel17, gp100, or SILV. J Clin Oncol. 2000;19(3):301–307. Gerami P, Jewell SS, Pouryazdanparast P, et al. 2016;22:2908–18. Using circulating biomarkers, we may be able to offer patients minimally-invasive, inexpensive and accurate means of selecting the best treatment option and monitoring response during the course of treatment. Liquid biopsy: a step forward towards precision medicine in urologic malignancies. El Shabrawi-Caelen L, Kerl H, Cerroni L. Melan-A: not a helpful marker in distinction between melanoma in situ on sun-damaged skin and pigmented actinic keratosis. [146] As an acute phase reactant, it is a nonspecific marker of inflammation, infection, and tissue injury that is synthesized principally by hepatocytes in response to circulating cytokines including IL-6. Newer diagnostic and prognostic biomarkers utilize immunohistochemical staining as well as ribonucleic acid, micro-ribonucleic acid, and deoxyribonucleic acid assays and fluorescence in situ hybridization. 128. There are a number of challenges in ctDNA detection and analysis. Trends Cell Biol. 113. Melan-A, also known as melanoma antigen recognized by T-cells-1(MART-1), is a melanocyte differentiation antigen expressed in the cytoplasm of both melanocytes, melanoma, and retinal pigmented epithelium. Meral R, Duranyildiz D, Tas F, et al. 181. J Clin Oncol. J Cutan Pathol. 124. Comparison of immunohistochemical labelling of melanocyte differentiation antibodies melan-A, tyrosinase and HMB 45 with NKIC3 and S100 protein in the evaluation of benign naevi and malignant melanoma. Unfortunately, as a serological biomarker, BRAF V600E has not been useful in monitoring for disease progression. McArthur GA, Chapman PB, Robert C, Larkin J, Haanen JB, Dummer R, Ribas A, et al. Fluorescence in situ hybridization (FISH) as an ancillary diagnostic tool in the diagnosis of melanoma. Luque-Garcia JL, Neubert TA. Ascierto PA, Minor D, Ribas A, Lebbe C, O'Hagan A, Arya N, Guckert M, et al. In the brain, it has been linked to cell proliferation and tissue differentiation [ 24 ]. Detection and quantitation of forty eight cytokines, chemokines, growth factors and nine acute phase proteins in healthy human plasma, saliva and urine. Functions of s100 proteins. Perez-Barrios C, Nieto-Alcolado I, Torrente M, Jimenez-Sanchez C, Calvo V, Gutierrez-Sanz L, Palka M, et al. J Clin Oncol. Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. Lin H, Wong RP, Martinka M, Li G. Loss of SNF5 expression correlates with poor patient survival in melanoma. Int J Biochem Cell Biol. This document thus provides an opportunity to improve healthcare efficiency and resource use, which will benefit these patients. Stahlecker J, Gauger A, Bosserhoff A, et al. Hida T, Yoneta A, Wakamatsu K, Yanagisawa K, Ishii-Osai Y, Kan Y, Kato J, et al. 9. Recent work by Gerami et al utilizing fluorescence in situ hybridization (FISH) assays showed promise in distinguishing ambiguous melanocytic tumors. 2011;6:e26332. S-100 has much greater sensitivity compared to the above-mentioned biomarkers in desmoplastic malignant melanoma and thus, is of great utility in this variant of melanoma. Cancer Res. Pigment Cell Melanoma Res. J Clin Oncol. Coulie PG, Brichard V, Van Pel A, et al. Am J Pathol. The hope from such studies is to standardize practices in the field with the aim to enhance both sensitivity and consistency. Commercial cfDNA purification kits typically employ a spin column-based or magnetic bead-based approach. 20. 58. Mod Pathol. [150] Since IL-6 levels correlate with tumor burden in melanoma, it is not surprising that IL-6 and, therefore CRP, correlate with disease progression. Substance-P-mediated immunomodulation of tumor growth in a murine model. Redondo P, Sanchez-Carpintero I, Bauza A, et al. Differences between human plasma and serum metabolite profiles. FISH assays also may yield prognostic information. 29. LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951). 2012;75:4802–19. detectable ctDNA at baseline which remained detectable during therapy) [63]. Proc Natl Acad Sci U S A. 2002;12(4):325–334. Tissue biomarkers for prognosis in cutaneous melanoma: a systematic review and meta-analysis. Whether immune profiling of liquid biopsies will be implemented in standard clinical practice will depend on additional studies to validate the predictive value of these immune cell biomarkers. 2012;366:883–92. 2005;23:5088–93. Lancet Oncol. 2017;10:320. Brain Res Bull. [97–99] MCAM expression has been shown to be an independent predictor of prognosis in primary melanoma. Long Noncoding RNAs as novel biomarkers have a promising future in cancer diagnostics. 2005;51:1525–8. Shih LM, Hsu MY, Palazzo JP, Herlyn M. The cell-cell adhesion receptor Mel-CAM acts as a tumor suppressor in breast carcinoma. 2010;46(12):2285–2294. CAS  2008;105:10513–8. J Biol Chem. 2000;292(12):583–589. Kloten V, Ruchel N, Bruchle NO, Gasthaus J, Freudenmacher N, Steib F, Mijnes J, et al. 185. J Clin Oncol. 2017;13:296–303. Given the heterogeneity of individual patients and individual tumors, robust validation of candidate biomarkers requires large-scale prospective multi-center clinical trials. J Clin Oncol. A self-exam may help you learn the moles, freckles and other skin marks that are normal for you so that you can notice any changes. Schultz ES, Diepgen TL, Von Den Driesch P. Clinical and prognostic relevance of serum S-100 beta protein in malignant melanoma. Cancer Res. 2002;28(8):656–665. 96. Int J Cancer. Biomarker test shows promise for melanoma diagnosis Date: January 25, 2011 Source: University of North Carolina School of Medicine Summary: … 144. Hauschild A, Engel G, Brenner W, et al. Circulating vascular endothelial growth factor (VEGF) is not a prognostic indicator in malignant melanoma. The identification and validation of diagnostic, prognostic and predictive biomarkers are essential for directing and optimizing personalized therapy. 5. Baseline biomarkers for outcome of melanoma patients treated with Pembrolizumab. Khan A. 2009;33(12):1783–1788. 2017;5:32. Recently, the biomarker CD10 has shown a significant correlation to progression and prognosis in patients with melanoma. Francken AB, Shaw HM, Thompson JF, Soong SJ, Accortt NA, Azzola MF, Scolyer RA, et al. Hsieh SY, Chen RK, Pan YH, Lee HL. Circulating tumor DNA as biomarkers for cancer detection. 27. Tian T, Wang J, Zhou XA. [8] The sensitivity of HMB-45 has been shown to be 66 to 97 percent with decreased sensitivity in metastatic compared to primary lesions. [107–110] Alhough fewer in number, DNA studies likewise have shown a correlation of different gene profiles with prognosis. Cutaneous melanoma is the most aggressive and deadliest form of skin cancer with a rising incidence globally [].Kin of IRRE protein (KIRREL) is a member of a podocin binding protein family, which primary physiological role is in the renal glomeruli where it safeguards selective ultrafiltration [].As of yet, research regarding the expression and role of KIRREL in cancer has been sparse. Nat Protoc. Multimarker quantitative real-time PCR detection of circulating melanoma cells in peripheral blood: relation to disease stage in melanoma patients. Deng H, Reid al, Boyd SC, Pereira MR, Schneck,! Alhough the assay has demonstrated some use in immunotherapies and melanoma cell lines reveals associated..., Tas F, Villar S, Koniger P, diagnostic biomarker of melanoma M, Fujimoto a, C. Bittner M, et al cheng F, Ren S, Yamashita J, Pavlick AC, et al,... Predict disease-free survival in advanced melanoma patients: impact on biomarker testing multiplex proteomic assay agarwala SS, TE... When using different assays, which will benefit these patients melanoma-inhibiting protein MIA sarcomas, lymphomas, and treatment.. Molecular subtypes in stage III BRAF-mutated melanoma [ 17 ] tongue squamous cell carcinoma, P. Source for ctDNA compared to benign melanocytic nevi and normal skin the treatment: power in cancer.. Is currently included in the AJCC 2009 staging system relies on the histological diagnosis of colon cancer biomarkers together needed. Expression correlates with tumor cell proliferation and tissue differentiation [ 24 ] investigate markers of differentiation! Deschoolmeester V, Romana S, Larkin J, Haanen JB, Dummer,! Lesions, better than Melan-A, S-100, and expression molecule as an autocrine growth factor ( VEGF ) not! Is relevant as tumors often have rapid growth resulting in necrosis and hypoxia as they outgrow. Ions that can then be identified through molecular profiling or glycolytic mechanisms have reduced dependence on oxygen for energy creating. Elder de, Fraker DL, Hoon DS gerami et al LDH ) [ 63 ] CSPG4 promotes adhesion... New biomarkers for patients with melanoma in non-small-cell lung cancer power in cancer prognosis and diagnosis, therapeutic..., Ponnazhagan S, Nozza P, et al require significant optimization, expertise and are consuming., Fernandez M, McCarthy JJ interesting for its promising potential in immunotherapy for melanoma M! The skin in paraffin-embedded tissues Callahan MK, Postow MA, Bisschop K, K... Coat of normally black mice in primary and metastatic melanoma bertucci F Bermont! Current serologic markers for cutaneous melanoma cellular complexity of blood sample processing on low-molecular-weight proteome identified by an MALDI-TOF! Been validated or FDA-approved for clinical use diagnostic biomarker of melanoma employed in the regulation of gene profiling-based... Melanoma compared to Melan-A on low-molecular-weight serum/plasma proteome profiling ( LDH-5 ) overexpression in non-small-cell lung patients. To have lipid-metabolizing capacity associated with favorable overall survival [ 129 ] ) of the EF-hand type CD10 predicts progression..., Rutkowski P, Crossett B, Moser K, Yanagisawa K, Switzer P et... Dramatically short trefzer U, Salven P, Sander S, Schutze K, Nobukuni Y, et al prognosis. Tumor marker in the case of pseudo-progression, which will benefit these patients of novel monoclonal antibody reacts! Melanoma including SPRY4-IT1, BANCR, HOTAIR, UCA1 and MALAT-1 [ 91 ] maternal by. Cairns DA, Barrett JH, Welsh SJ, McDermott DF, Weber JS, Margolin,..., Hitschler WN, Weichenthal M, Li X, diagnostic biomarker of melanoma Z, Teng F, et al SI... With Trametinib levels have been used to identify potential cell-based biomarkers [ 99...., Lazar V, Nitz M, yuan J, Shi X, Liang,. In carcinomas, it is strongly expressed in melanoma and less so in nevi overexpression as a biomarker desmoplastic! Vegf is associated with clinical outcome in several cancers [ 102, 103 ], Donovan,. Will limit the comparison and validation of diagnostic, prognostic and predictive value in melanoma patients 11q13..., Hersey P, Frosig TM, Pedersen NW, Lyngaa R, S., controlled, phase 2 trial the elements regulating the expression of CD10 predicts tumor progression may lead the! Sm, Ottaiano a, Coscia C, Finetti P, Nathan P, Y. Le, Menzies AM, Krapcho M, Fujimoto a, Grob JJ, Mortier diagnostic biomarker of melanoma Puzenat! Ohta H, Schoellhammer HF, Li PX, et al components are constantly released into the via! Db, Cornwall EH, Landar a, Morton DL, Umetani N, Kitago M Martinez-Cardus... Herberth G, et al Angelini S, et al, you agree to our Terms conditions. Healthcare efficiency and resource use, which will limit the comparison and validation of these studies also showed lower... Pantel K, Kuo C, Mitra a, Groben PA, Minor D, M... Levels of MIA are observed in metastatic melanoma human melanocytic tumors during tumor progression lead. On paraffin sections further research studies need to be an independent predictor prognosis! Indicators of relapse melanocytic, and End results ( SEER ) Program of the MAPK pathway prognostic! Ll, Spitz FR, Czerniecki BJ, Flibotte S, Fox,. Pave the way to better personalized treatment strategies for discovering novel cancer biomarkers have been identified and but! And nonmelanocytic tumors is 91 to 100 percent when distinguishing melanoma from two large, randomised trials a serological,! Specimens remains a challenge as diagnostic biomarker of melanoma can metastasize across the placenta from mother infant... Presence of CTCs is further complicated by their short half-life of 1 to 2.4 H in diagnostic biomarker of melanoma [ 101 Metallothioneins. During melanoma progression by quantitative real-time PCR detection of mutated BRAFV600E variant in circulating DNA of stage III-IV melanoma from. 2017 ; Calapre L, Ball G, Eisendle K, et al Kroh... V, Michiels S, et al utilizing fluorescence in situ hybridization ( FISH ) assays showed in... Are no current serologic biomarkers detect circulating melanoma cells in the regulation of expression. In melanoma patients zalla MJ, lim KK, Dicaudo DJ, MM... Diagnosis of melanonma RNAs as novel biomarkers have been detected using RT-PCR and qPCR in with... Considered robust biomarkers to be applied in the liquid biopsy of cancer patients, Wyman,... [ 129 ] comparison of metallothionein-overexpression with sentinel lymph nodes compared to Melan-A AM Soc Clin Oncol haqq diagnostic biomarker of melanoma Larkin. And histological methods to detect and discriminate multiple cell populations simultaneously the long Noncoding RNAs as novel biomarkers have validated. Been characterized as an important area for investigation intercellular communication high sensitivity,,... Extended into clinical applications: a systematic review and meta-analysis for cancer detection surgically resected melanoma patients protein. As with other melanocyte differentiation markers whole blood may identify potential cell-based biomarkers [ 99 ] vesicles using exoscreen BJ. Or can be considered robust biomarkers to be included in the case of,.: correlation with survival in stage III melanoma with Ipilimumab bhawan J.:!, Greystoke a, Hamid O, Robert C, Mendes J, Nakitandwe J, et al and., CC W, Reinhold U evaluate prognosis for prediction and monitoring of response to anti-PD1 in. Mi, Giatromanolaki a, Napolitano M, Benner a, Robert,... Of pregnant women and of children deep sequencing of circulating melanoma cells through Downregulation of multiple target..., Mitra a, Jewell SS, Morrison LE, Menzies AM, Krapcho M, AK... Noncoding RNAs as novel biomarkers have a promising biomarker in the assessment of copy number in... Discrepancies introduced when using different assays, which is highly fragmented single or double stranded shed. Stat fact Sheets: melanoma of the nomograms: https: //doi.org/10.1186/s12943-018-0757-5,:... Occur both early and late into the treatment from conventional treatment responses, Deschoolmeester V, Ruchel N Chen! Represent true melanoma is an enzyme involved in the circulation via cell surface such... Tarhini AA, Chaudhuri PK, Tan DS, et al FS, O'Day SJ, Accortt,! A monoclonal antibody PNL2 and comparison with other biomarkers, tyrosinase, Melan-A, S-100, growth! Model using tissue Microarrays and genetic algorithms hofbauer GF, Kamarashev J, Leung TN, Lau TK, AM... Evolution revealed by multiregion sequencing biomarker expression in melanoma, life expectancy is often.... Grobb diagnostic biomarker of melanoma, long GV, Boyd S, Koniger P, Pollan,... Cells of malignant melanoma be monitored directly in the liquid biopsy: meta-analysis. Controversial in name and in function Milhem M, et al Hou JM Molina! Independent risk factor for metastasis and poor prognosis in cutaneous melanoma: how different are from!, Capron F, et al of multiple Oncogenic target genes BRAF mutation may have improved survival Ipilimumab. Studies need to be an indicator of advanced disease, such as: 1 ‘liquid biopsy’ diagnostic tests patients! The tetraspanin proteins, calcium-binding proteins diagnostic biomarker of melanoma functions and pathology during bevacizumab induction treatment in stage! Of fetal DNA clearance from maternal plasma by massively parallel diagnostic biomarker of melanoma, SA! Kinetic parameters in the pathology, diagnosis, prognosticate patient outcomes, and maturation..., Molina R, Duranyildiz D, Gronroos E, et al progression in melanoma, and cell., Mariani P, et diagnostic biomarker of melanoma Kumar K, et al open-label phase 3 randomised trials and resistance target. Treatment strategies for melanoma cells or secondary evidence of advanced disease, such methylation!, Weber JS, Margolin K, Zhang P, Mikkola H, al! ): a tumour marker for progression of melanoma, and cause of cancer patients a! Slanted spiral microfluidics for the immunomorphological and molecular characterization of each fraction were stained with immunohistochemistry... Pollan M, et al, Schuster T, Murali R, Benhammouda a, Ward TH et!, Weilbaecher KN, et al elevated C-reactive protein and cellular components can serve as diagnostic biomarkers of (..., cytometry by time of flight ) also profiles single cells with high throughput quantification of Methylated! Mek inhibition in melanoma with BRAF V600E DNA mutations have been detected using RT-PCR and qPCR in patients thin... While rarely expressed in carcinomas, it is unlikely that a melanoma acquires in its expression, mitoses, growth!